Restructuring Costs

9 Months Ended

Sep. 30, 2016

Restructuring and Related Activities [Abstract]

Restructuring Costs

12. Restructuring Costs

In June 2016, the Company halted investment in PNT2258 and the DNAi platform and closed the related Phase 2 clinical trials to further enrollment. As a result, the Company closed its research facility in Plymouth, Michigan, renegotiated and terminated certain contracts, and implemented staff reductions in the United States and Canada.

The following table summarizes restructuring activities for the three months ended September 30, 2016:

	Contract Termination			Employee Termination			Asset Impairment		Total
	(in thousands)
Accrual balance at June 30, 2016	$	2,093		$	57		$	—	$	2,150
Adjustments to research and development expense		(420	)		—			—		(420	)
Restructuring costs charged to general and administrative expense		—			100			—		100
Cash payments		(254	)		(101	)		—		(355	)
Accrual balance at September 30, 2016	$	1,419		$	56		$	—	$	1,475

Adjustments to research and development expense include revisions to estimated costs to close the PNT2258 Phase 2 clinical trials.

The following table summarizes restructuring activities for the nine months ended September 30, 2016:

	Contract Termination			Employee Termination			Asset Impairment			Total
	(in thousands)
Accrual balance at December 31, 2015	$	—		$	—		$	—		$	—
Restructuring costs charged to research and development expense		2,367			—			—			2,367
Restructuring costs charged to general and administrative expense		5			286			130			421
Non-cash charges		(681	)		—			(130	)		(811	)
Cash payments		(272	)		(230	)		—			(502	)
Accrual balance at September 30, 2016	$	1,419		$	56		$	—		$	1,475

The accrual balance is expected to be fully paid in early 2017.

There were no restructuring activities during the three and nine months ended September 30, 2015.